Extraventricular neurocytoma (EVN) is a rare neoplasm described in the 2007 World Health Organization classification of tumours of the nervous system. Due to the rarity of the tumour, there is limited literature available. The clinical characteristics, pathological features, biological behaviour and outcome of EVN remain unclear, and there are challenges regarding its diagnosis and management. The present case was a 75-year-old man who had been experiencing slow responses to stimuli for 1 month prior to hospital admission. A diagnosis of atypical EVN was made on the basis of pathology and immunohistochemistry results. Atypical pathological features included vascular proliferation, the presence of mitosis and a high MIB-1 (an antibody against Ki-67) labelling index. The disease recurred 7 months after the initial complete resection and radiation treatment, presenting with dural metastasis and codeletion of chromosomes 1p/19q. The present case history and treatment course are discussed with respect to the literature.
Introduction
Neurocytoma, also known as central neurocytoma (CNC), is a rare neoplasm that usually arises from the lateral ventricles but has been reported in a variety of other locations. 1 Extraventricular neurocytoma (EVN) 2 was initially described in the 2000 World Health Organization classification of nervous system tumours, 3 but remained unclassified until 2007. 4 Due to the rarity of the tumour, its clinical characteristics, pathological features, biological behaviour and outcome remain unclear. The present report describes a case of atypical EVN, with the unusual features of dural metastasis and codeletion of chromosomes 1p/19q.
Case report
A 75-year-old man presented at the Department of Neurosurgery of the Second Affiliated Hospital of Zhejiang University, Zhejiang, China, during February 2010, having experienced slow responses, to stimuli such as audio or visual stimuli, for 1 month prior to hospital admission. There was no history of headache, blurred vision or seizure, and no neurological deficit on physical examination. The patient had type II diabetes, which was under good control.
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Magnetic resonance imaging (MRI) revealed a cystic lesion of 5.5 × 4.0 × 4.2 cm in the left occipital-parietal lobe (Fig. 1 ). The cystic wall of the lesion was dramatically enhanced after administration of gadolinium diethylene triamine penta-acetic acid ( Fig. 1) . A glioma or metastatic tumour was suspected.
A left occipitoparietal craniotomy was performed on day 4 after admission. Microscopic dissection revealed a subcortical cystic lesion containing clear, straw yellowcoloured fluid within a smooth, soft, pinkishgrey cystic wall. The lesion was completely removed. Histological examination revealed a tumour of moderate cellularity, containing small, round cells with slightly eosinophilic or clear cytoplasm, closely resembling the 'fried-egg' appearance of an oligodendroglioma ( Fig. 2A -2C ). Dispersed neuropil islands were present (Fig. 2C ), and sporadic large ganglion cells were observed focally. The tumour showed vascular proliferation ( Fig. 2A ) but necrosis was not observed. The mitosis rate was 6 -8 cells/10 high-power fields (HPF).
Neoplastic cells exhibited strong diffuse immunoreactivity for synaptophysin (Syn) Pathologists suspected neurocytoma or oligodendroglioma, but it was difficult to make a firm diagnosis due to some unusual pathological characteristics (discussed below). After a discussion with pathologists at the University of California at Los Angeles, Los Angeles, CA, USA via a remote diagnosis system (online video channel), a diagnosis of atypical EVN was made. The patient had an uneventful postoperative course. A total dose of 64 Gy of local fractional radiation therapy was administered in 32 fractions.
The patient was readmitted to the Department of Neurosurgery of the Second Affiliated Hospital of Zhejiang University 7 months after surgery due to sudden-onset anepia. MRI revealed a solid tumour along the frontotemporal dura with an intratumoural haemorrhage, but no evidence of tumour recurrence in the first operative area ( Fig. 3 ). A frontotemporal craniotomy was performed, revealing a welldefined pinkish-grey, fragile tumour that bled easily and contained dark blood clots (Figs. 4A -4C). The tumour adhered to the dura and could be easily separated from the cortex. Total resection was achieved (confirmed by MRI).
Haematoxylin and eosin (H&E) staining revealed similar pathological features to the previous specimen, but with greater cellularity than before. The results of immunohistochemical staining were identical to those recorded for the previous tumour, and the MIB-1 LI was > 34%. The tumour was confirmed as dural metastasis of the atypical EVN. Fluorescent in situ hybridization was performed and the loss of chromosomes 1p and 19q was identified (Fig.  4D) .
The patient received a total dose of 56 Gy local frontotemporal fractional irradiation in 28 fractions and five cycles of temozolomide chemotherapy (200 mg/m 2 per day, orally, for 5 days/month). The patient was well, with no MRI-detected tumour recurrence, 9 months after the second surgery and was also well at the time of publication.
Discussion
The diagnosis of EVN presents a challenge to the neuropathologist. The tumour resembles oligodendroglioma, in that it is composed of small round cells with a finely granular, slightly eosinophilic cytoplasm and occasional artefactual vacuolations. The morphological spectrum of EVN is wider than that of CNC, with sheets, clusters, or rosette-like arrangements of neurocytes and neuropils either dispersed in broad zones (neuropil islands) between these cell arrangements or localized within the rosettes. 2, 5 Immunohistochemistry can be helpful in differentiating EVN from oligodendroglioma; EVN generally exhibits strong Syn immunoreactivity and is negative for GFAP, whereas oligodendroglioma is strongly positive for GFAP and has little or no Syn immunoreactivity. 1, 6, 7 In addition, EVN is positive for neuronal markers such as NSE, tau protein, α-synuclein, neuron-specific antigen L1 and neuronal nuclear antigen, which are helpful in the diagnosis of this condition. 8 -11 Extraventricular neurocytomas are defined as atypical in the presence of anaplastic features including focal necrosis, vascular proliferation and increased mitotic activity (≥ 3 cells/10 HPF). 2 The atypical designation is supported by a MIB-1 LI of > 5%, indicating increased cell proliferation, although this is not used as an independent diagnostic parameter. 2 The case described here presented without necrosis and with MIB-1 LI of 30% and 34% at first presentation and at the 7-month follow-up, respectively. Thus, necrosis is not necessarily a feature of atypical EVNs. The most striking feature of the present case was the appearance of dural metastasis 7 months after initial total gross resection and local radiation treatment. This is only the third case of disseminated EVN to be described. A 24-year-old man with a recurrent primary atypical spinal neurocytoma presented with spinocranial dissemination and evidence of metastasis in the cerebellar vermis 4 months after a second surgery, 12 and a 71-year-old woman with a solid occipital EVN exhibited subarachnoid seeding after biopsy and radiation therapy. 2 In addition, two cases of disseminated neurocytoma designated as extraventricular central neurocytoma have been reported, 13 but these would have been more appropriately diagnosed as CNC, because MRI revealed no evidence of dissemination. 14 No predictive indicator of dissemination has been described, but an uncommonly high MIB-1 LI, atypical histological features and advanced age are associated with an increased likelihood of recurrence. 3 The MIB-1 LI is related to proliferative potential and is believed by some to be the best indicator of poor outcome. A previous study determined a relapse rate of 22% after a 150-month follow-up period for patients with MIB-1 LI < 2%, compared with a rate of 63% in patients with MIB-1 LI > 2%. 15 The MIB-1 LI has been shown to be significantly higher in recurrent EVNs (often > 5%), but atypical histology was only slightly more common in recurring tumours. 2 The mean MIB-1 LI was 1.6 for well-differentiated EVNs and 6.6 for atypical EVNs. 2 The MIB-1 LI in the present case was considerably higher than these reported means, suggesting a relationship with tumour dissemination. The advanced age of the patient and atypical tumour histology may also have contributed to dissemination. The codeletion of chromosomes 1p/19q in the present case is a common feature of oligodendroglioma and is a statistically significant predictor of tumour sensitivity to chemotherapy. 16 Some researchers argue that the codeletion of chromosomes 1p/19q is specific to oligodendroglioma, and it has been proposed as a diagnostic marker for this tumour. 17, 18 Other reports have, however, also documented the codeletion of chromosomes 1p/19q in 17% 19 or 24% 4 of EVNs.
There is limited information available on the management of EVN. Complete resection remains the first treatment choice, since the extent of resection is a key determinant of recurrence. 2 The value of radiation therapy as adjunct therapy is debatable, but most clinicians agree that radiation therapy should be provided in cases of incomplete resection or atypical histology. 2, 20, 21 Since only three cases of EVN metastasis have been reported, the risks of whole-brain irradiation may outweigh the benefits. The present case underwent local radiation therapy after both resection surgeries. Chemotherapy has only been used in a few EVN cases, including four patients who received chemotherapy after radiation, resulting in no tumour progression. 22 In a small patient series from the Mayo Clinic, two patients with EVN, with codeletions of 1p/19q, received temozolomide chemotherapy. 4 The present case received temozolomide chemotherapy after the second resection, but the effect of this treatment is unclear due to the brevity of the follow-up period, although the patient was well at the time of publication.
The rarity and novelty of EVN leaves many unanswered questions regarding its diagnosis and treatment, and further studies and case reports are needed to resolve these issues.
